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1 Abstract
2 Background: The continuation of preventive drugs for older patients with advanced cancer has come 
3 under scrutiny since these drugs are unlikely to achieve their clinical benefit during the patients’ 
4 remaining lifespan.
5 Patients and methods: nationwide cohort study of older adults (≥65 years) with solid cancer who died 
6 between 2007 and 2013 in Sweden, using routinely collected data with record linkage. We calculated 
7 the monthly utilization and cost of preventive drugs throughout the last year before death.
8 Results: Among 151 201 older patients who died with cancer (mean age 81.3 [SD, 8.1] years), the 
9 average number of drugs increased from 6.9 to 10.1. Preventive drugs were frequently continued until 
10 the final month of life, including antihypertensives, platelet aggregation inhibitors, anticoagulants, 
11 statins, and oral antidiabetics. Median drug costs amounted to $1482 (interquartile range [IQR] $700–
12 $2896]) per person, including $213 (IQR $77–$490) for preventive therapies. Compared to older adults 
13 who died with lung cancer ($205, IQR $61–$523), costs for preventive drugs were higher among older 
14 adults who died with pancreatic cancer (adjusted median difference [AMD] $13, 95% CI $5–$22), or 
15 gynecological cancers (AMD $27, 95% CI $18–$36). There was no decrease in the cost of preventive 
16 drugs throughout the last year of life.
17 Conclusion: preventive drugs are commonly prescribed during the last year of life of older adults with 
18 cancer and are often continued until the final weeks before death. Adequate deprescribing strategies are 
19 warranted to reduce the burden of drugs of limited clinical benefit near the end of life.
20 Keywords: palliative care; end-of-life; drug prescribing; deprescribing
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1 Introduction
2 In high-income countries, people aged 70 years and older now account for almost two-thirds of cancer-
3 related deaths.1 Chronic multimorbidity has thus become the norm rather than the exception in 
4 oncology2, and is associated with poorer chances of survival and with a higher burden of functional 
5 impairments and physical symptoms.3 Multimorbidity also comes with a higher burden of long-term 
6 pharmacological treatments. In the United States and in Europe, about 40% of people aged 65 years or 
7 older use 5 or more drugs concomitantly.4,5 This polypharmacy is particularly problematic among older 
8 people with advanced cancer6, since the potential to develop serious drug–drug interactions is amplified 
9 by the use of anticancer agents and complementary medicines.7,8 Moreover, the probability of 
10 experiencing adverse drug reactions increases because the main pharmacokinetic parameters are 
11 affected not only by age but also by the physiological impact of cancer (e.g. modified drug absorption 
12 due to gastrointestinal symptoms or to impairments in the gut wall function, decrease in the volume of 
13 distribution caused by weight loss, renal impairment due to the nephrotoxicity of chemotherapy).9,10 
14 Beyond pharmacology, polypharmacy in the context of advanced cancer also raises important questions 
15 from a clinical and ethical viewpoint. As cancer progresses and prognosis worsens, the net benefit of 
16 each additional medicine gradually decreases while the risk of harm increases. This “law of diminishing 
17 returns” makes the continuation or initiation of long-term treatments particularly questionable for older 
18 patients with advanced cancer. Preventive drugs are prescribed either to avert or delay the onset of a 
19 disease among individuals who are considered at high risk of developing that disease in the future 
20 (primary prevention), or to avoid the recurrence of a condition that the patient experienced in the past 
21 (secondary prevention). These drugs typically need several years before the physiological and 
22 biological changes that they produce translate into measurable and clinically meaningful health 
23 outcomes. Thus, the time-until-benefit of preventive agents is often much longer than the remaining 
24 lifespan of older adult with serious illness.11 Recent randomized controlled trials show that lipid-
25 lowering medications can safely be deprescribed among older adults with limited life expectancy, and 
26 that the discontinuation of antihypertensives among individuals without cardiovascular disease is safe 
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1 in the short term.12,13 Other long-term treatments such as bisphosphonates retain their effect 3 to 5 years 
2 after their withdrawal.14 Nevertheless, a handful of observational studies have reported that preventive 
3 medications are prescribed during the last year of life of patients with life-limiting disease, and have 
4 cast doubt upon the benefit of these treatments.15 There is limited investigation to date of the 
5 continuation and discontinuation of medications throughout the last months of life and with little 
6 information about the costs of these medications and about potential variation across cancer types. The 
7 aim of the current study was therefore to evaluate the prescribing of preventive drugs throughout the 
8 final year of life of older adults who died with cancer across Sweden, and to estimate the direct costs 
9 of preventive drugs.
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1 Methods
2 Study design and data
3 This was a retrospective cohort study based on routinely collected data in Sweden, a country with a 
4 universal healthcare system. Data from the National Cause of Death Register were linked through 
5 deterministic matching to the Total Population Register, the National Patient Register, the Swedish 
6 Prescribed Drugs Register, the Social Services Register, and the Swedish Register of Education. The 
7 Regional Ethical Review Board in Stockholm approved the study.
8 Study population
9 We included older adults aged ≥65 years who died in Sweden between 2007 and 2013, as these were 
10 the most recent available data. Decedents were considered as eligible for inclusion if a diagnosis of 
11 solid cancer (International Classification of Diseases [ICD], 10th revision codes C00–C76 and C80) was 
12 reported either in a hospital discharge report during the last 2 years of life, or as an underlying or 
13 contributing cause of death. We decided a priori to exclude decedents with missing cause of death, 
14 those with missing drug prescription history throughout the last 6 months of life, and those who 
15 remained hospitalized continuously during the last 3 months before death. Older adults with 
16 concomitant hematological malignancies (ICD-10 codes C81–C95) were also excluded, in order to 
17 select a homogenous population of individuals diagnosed only with solid cancer. Previous studies have 
18 indeed shown that persons with hematological malignancies experience a rapid functional decline at the 
19 end of life, which makes survival prediction particularly challenging. The potential for cure until late 
20 in the course of the disease trajectory differentiates these older patients from those dying with solid 
21 cancer.16,17
22 Outcomes
23 Utilization and cost of preventive drugs during the last 12 months of life were the main study outcomes. 
24 Preventive drugs with questionable benefit near the end of life have been identified in a recent 
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1 systematic review of the literature15, and include drugs for diabetes, vitamins, mineral supplements, 
2 antithrombotic agents, antihypertensives, statins, bisphosphonates, and medications for chronic anemia. 
3 The list of corresponding Anatomical Therapeutic Chemical (ATC) classification codes is available in 
4 Supplementary eTable 1. 
5 We computed monthly exposure to specific drug classes based on data from the Swedish Prescribed 
6 Drugs Register, which contains detailed information about all prescription drugs delivered in 
7 community pharmacies in Sweden since 2005 (including drugs dispensed to nursing home residents, at 
8 the exception of a few facilities with their own drug storeroom). Methods for constructing periods of 
9 drug exposure have been presented in detail elsewhere 5,18, and are illustrated in eFigure 1A. 
10 Continuation of preventive drugs was calculated as the proportion of older adults who were still using 
11 preventive drugs during the last month before death among those exposed one year before, while 
12 initiation was calculated the proportion of older adults who started using preventive drugs during the 
13 last year of life. Drug costs were estimated through a two-step approach, as described in eFigure 1B. 
14 We first divided the total cost of each purchase by the number of days covered to obtain the average 
15 daily cost. Second, we multiplied this average daily cost by the expected number of days of exposure 
16 during a given month, which allowed for distributing drug costs according to the assumed length of 
17 exposure. This approach provides a more realistic estimate of the costs, instead of artificially 
18 concentrating all expenditures at the purchase date. Drug costs were standardized using the harmonized 
19 index of consumer prices (HICP) with 2013 as reference year in order to correct for inflation over time 
20 and were then converted from the Swedish currency SEK into US dollars (USD) based on the European 
21 Central Bank average exchange rate from 1 January to 31 December 2013 to facilitate international 
22 comparisons (1 SEK = 0.1535 USD) .
23 Assessment of individual characteristics
24 Sex and date of birth were extracted from the Total Population Register and cross-validated with data 
25 reported on study participants’ death certificates. We categorized solid malignancies into 14 distinct 
26 locations. Details about the corresponding ICD-10 codes are presented in eTable 2. The overall burden 
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1 of chronic multimorbidity was measured with a recently validated tool that captures a set of 60 distinct 
2 chronic diseases based on different data sources (contributing causes of deaths, inpatients and 
3 outpatients diagnoses reported during the last 3 years of life, and specific drugs unequivocally linked 
4 to chronic conditions).19 Living arrangement at time of death was defined as “community” or “nursing 
5 home”, while the place of death was reported as either “hospital” or “usual place of living”. The 
6 decedents’ level of education was categorized into “primary”, “secondary”, and “tertiary” education in 
7 accordance with the International Standard for Classification of Education.
8 Statistical analysis
9 Multivariable quantile regressions were used to model drug costs across different cancer types, while 
10 controlling for sex, age, number of chronic diseases, living arrangement, and level of education. While 
11 linear regression allows for modeling the mean of an outcome, quantile regression is used to model 
12 quantiles of the outcome when the distribution of the outcome is highly skewed.20 Beta coefficients 
13 obtained from quantile regression models can be interpreted as the adjusted median difference (AMD) 
14 in costs compared with the reference group, and are reported together with their 95% CIs. We compared 
15 the results with estimates drawn from generalized linear models with log link function and gamma 
16 distribution, to ensure that the average median effects reported in our study are concordant (in both 
17 direction and magnitude) with average mean effects.21 Variations in the cost of preventive drugs were 
18 then represented graphically in a series of contour graphs plotting the average cost by age at death and 
19 number of comorbidities. Two sets of sensitivity analyses were performed to mitigate the risk of bias 
20 due to the potentially unpredictable time of death of older adults with cancer, which would explain why 
21 preventive drugs were continued until the very end of life: we first excluded patients whose underlying 
22 cause of death suggested an acute and sudden fatal event who died from acute and possibly 
23 unpredictable causes (eTable 4); then, we then stratified the main analyses according to the time 
24 between cancer diagnosis and death, separating decedents who were diagnosed more than 12 months 
25 before death from those who were diagnosed during the last 6 months of life. Individuals with missing 
26 data for the time between diagnosis and death (n=7863, 5.2%) were excluded from thise sensitivity 
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1 analysis. Statistical analyses were performed using JMP version 13.0 (SAS Institute Inc) and Stata 
2 version 14.1 (StataCorp LP). This study adheres to the RECORD  guidelines (Supporting file).22
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1 Results
2 Characteristics of the study population
3 Among a total of 165 821 older adults who died with cancer in Sweden between 2007 and 2013, 151 201 
4 (91.2%) met our eligibility criteria (Figure 1). Mean age at time of death was 81.3 years (SD, 8.1), 45% 
5 of decedents were women, 18% lived in nursing home facilities, and 47% died in hospitals. As shown 
6 in Table 1, the most common cancer types affected male genital organs (17%), respiratory organs 
7 (12%), and colon-rectum (11%). A large majority of patients had been diagnosed with cancer more than 
8 12 months (60%), or between 6 to 12 months (12%) before death. Hypertension, ischemic heart disease, 
9 heart failure, atrial fibrillation, and type 2 diabetes were the most commonly diagnosed comorbidities. 
10 Older adults who died without cancer reported as cause of death on their death certificate (n=29 984, 
11 19.8%) were, on average, older, lived more often in nursing homes, and had a greater number of chronic 
12 comorbidities than those who died from cancer (eTable4).
13 Use of preventive drugs
14 Throughout the last year of life, the mean number of prescribed drugs increased from 6.9 to 10.1 (mean 
15 difference 2.1, 95% CI 2.0–2.2) and the proportion of individuals using ≥10 drugs rose from 26% to 
16 52%. Preventive drugs were frequently prescribed near the end of life (Table 2). Antihypertensives were 
17 prescribed to 60.1% of the decedents during their last month of life, including beta-blockers (38.2%), 
18 angiotensin-converting-enzyme inhibitors (18.5%), and calcium channel blockers (15.9%). 
19 Antithrombotic agents, anti-anemics, lipid-lowering drugs, mineral supplements, and drugs for diabetes 
20 were also commonly prescribed. We observed little change in the use of preventive drugs over the 
21 course of the last year before death. The proportion of older adults who continued therapy until the final 
22 month of life ranged from 56.6% for bisphosphonates, to 65% for statins and vitamins, up to ≥80% for 
23 insulin, beta-blockers, and vitamin B12 or folic acid. Overall, 28.2% of decedents initiated 
24 antithrombotic agents (including 13.4% platelet aggregation inhibitors) during their last year of life, 
25 23.2% initiated high-blood pressure medications (including 13.3% beta-blockers), and 4.9% started 
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1 statins. Differences in the use of preventive drugs across cancer types are reported in eTable 5. In 
2 sensitivity analyses, results remained very similar after excluding individuals who died from acute and 
3 possibly unpredictable causes of death (eTable 6), or while comparing patients who had been diagnosed 
4 with cancer > 12 months before death to individuals who were diagnosed closer to death (eTable 7). 
5 Drug costs during the last year of life
6 The median drug cost during the last year of life was $1482 (interquartile range [IQR] $700–$2896]) 
7 per person, ranging from $961 among decedents with cancers of unknown primary site, to $1811 among 
8 women with breast cancer, up to $3073 among men with cancers affecting male genital organs (Table 
9 3). After adjusting for multiple confounders, we found significantly higher costs for patients with breast 
10 cancer, gynecological cancers, cancers of male genital organs, and multiple solid tumors, compared 
11 with individuals who died with lung cancer. Median monthly drug costs increased from $80 to $153 
12 over the course of the last year of life, although there was significant variation according to the type of 
13 cancer (eTable 8).
14 The median cost for preventive drugs during the last year of life amounted to $213 (IQR $77–$490) in 
15 the total study population and varied across cancer types. Compared to older adults who died with lung 
16 cancer ($205, IQR $61–$523), those who died with pancreatic cancer (adjusted median difference 
17 [AMD] $19, 95% CI $7–$31), breast cancer (AMD $19, 95% CI $11–$28), and gynecological cancers 
18 (AMD $27, 95% CI $18–$36) had the highest costs per person. Throughout the last year of life, the 
19 proportion of total drug costs corresponding to preventive drugs was 20.2%; this proportion decreased 
20 from 20.5% during the 12th month before death to 18.5% during the last month before death. However, 
21 despite this relative reduction, we found an absolute increase in the costs owing to preventive drugs 
22 (eTable 9). Overall, costs were highest among older adults aged less than 80 years and among those 
23 who had ≥5 chronic comorbidities, although our data shows that women with breast cancer had 
24 significantly higher costs for preventive drugs even with a low burden of chronic multimorbidity 
25 (eFigure 2). In sensitivity analyses, we found only marginal differences according to the time between 
26 diagnosis and death (eTable 10).
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1 Discussion
2 This large nationwide study has three main findings. First, a substantial share of older adults who die 
3 with solid cancer continues to receive preventive drugs until the final month of life. Second, preventive 
4 drugs account for around one fifth of the total costs of prescribed drugs, and this proportion decreases 
5 only slightly as death approaches. Third, there are important differences between cancer types in the 
6 use and costs of preventive drugs, which can only partly be explained by age and chronic 
7 multimorbidity. 
8 Our study builds on previous work exploring the utilization of preventive drugs in terminally ill 
9 patients.23,24 In Australia, Currow et al. showed that, patients were prescribed on average 2.6 drugs for 
10 managing comorbid conditions at the time of palliative care referral.25 Many patients who receive 
11 preventive cardiovascular drugs continue to do so until the very end of life.26,27 For instance, the 
12 prescribing of antihypertensive agents and platelet aggregation inhibitors is commonplace among 
13 hospice patients with advanced cancer.28 Recent studies have also shown that polypharmacy increases 
14 near the end of life, which is fueled not only by symptomatic drugs but also by the continuation of 
15 preventive agents until the very last weeks of life.18,24
16 The frequent continuation of long-term preventive drugs is indicative of insufficient deprescribing 
17 strategies at the end of life. Although the preventive drugs reported in our study are most often 
18 pharmacologically and clinically appropriate in the general population, their use in the context of 
19 limited life expectancy and palliative goals of care should be examined critically.29,30 Preventive 
20 medicines are not necessarily inappropriate at the end of life, as some may have palliative indications 
21 to avert distressing symptoms or to avoid serious complications (e.g. anticoagulants for managing 
22 cancer-related venous thrombosis). However, the large proportion of older adults with cancer who 
23 continue to receive statins, antihypertensives, vitamins and mineral supplements throughout the last 
24 year of life does suggest the existence of routine-based prescribing practices that contribute to low-
25 value care. Our finding that older adults with poor-prognosis cancers (e.g. brain, lung, liver, pancreas) 
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1 were just as likely as those with less aggressive disease to use preventive drugs during their last month 
2 of life suggests that there is room for deprescribing.
3 The question of whether drug treatments should be initiated or continued near the end of life is at the 
4 center of the Choosing Wisely campaign, which has been endorsed by the American Society of Clinical 
5 Oncology, the American Geriatrics Society, and the American Medical Directors Association. It is, for 
6 instance, explicitly recommended to refrain from using lipid-lowering agents in older patients with 
7 limited life expectancy. Evidence from a recent randomized controlled trial shows that discontinuing 
8 statins in this population is safe and can result in improved quality of life.12 Three components seem 
9 essential to reduce the burden of preventive drugs of limited benefit. First, timely physician-patient 
10 communication is needed to evaluate whether the prescribed treatments are concordant with the patient 
11 goals of care. Second, physicians should carefully consider whether the prescribed drugs are likely to 
12 achieve their benefit within the patients’ remaining lifetime. Third, the decision to initiate, continue or 
13 discontinue preventive treatments should account for the risk of the patient coming to harm.
14 From a health economics perspective, it can be argued that drugs account for only small share of the 
15 total healthcare expenditure, with hospital and long-term care being the major sources of medical 
16 spending at the end of life. In the United States, drugs-related costs (including drugs administered 
17 during hospital stays) amount to around 4% of the entire medical expenditure during the last year of 
18 life.31 However, at the patient level, these costs are substantial and may contribute to the ‘financial 
19 toxicity’ of treatments, especially in countries with no universal healthcare insurance coverage.32 It is 
20 worth noting that drug prices are generally much lower in Europe than in the United States, owing for 
21 the most part to strong price regulation within the European Union. In 2017, pharmaceutical 
22 expenditures amounted to $1162 per capita in the United States compared with $479 in Sweden.33 
23 Moreover, indirect costs (e.g. cost of International Normalized Ratio-testing associated with use of 
24 warfarin) and induced costs (e.g. hospital expenditures caused by severe adverse drug reactions) of drug 
25 prescribing also contribute to the overall burden of drug costs. 
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1 This is the first nationwide study that has explored drug utilization in the last year of life according to 
2 cancer type, and that has investigated the costs associated with these drugs. However, we acknowledge 
3 a number of limitations. First, it is possible that a fraction of patients included in the cohort died from 
4 sudden and totally unexpected deaths, which could explain why preventive drugs were continued until 
5 the time of death. Retrospective cohorts of decedents are indeed prone to confounding-by-indication 
6 bias and tend to underestimate the prognostic uncertainty surrounding end-of-life decisions.34 However, 
7 sensitivity analyses were performed in an attempt to separate sudden from non-sudden deaths, and 
8 showed only marginal differences regarding patterns of drug utilization at the end of life. Second, 
9 routinely collected data about drug dispensing do not allow for assessing whether drugs are actually 
10 consumed by patients, and do not provide information about dosage modifications that may occur 
11 between two refills. It is possible that some drugs were tapered off near the end of life, which our data 
12 would not reflect. Moreover, the estimations of drug costs relied on the assumption that patients used 
13 their treatments according to the prescribed daily dose. Although this assumption is unlikely at the 
14 individual level, it is reasonable to assume that, at a population level, variations from one patient to 
15 another cancel each other out. Also, since drugs administered during hospitalizations are not collected 
16 in the Swedish Prescribed Drugs Register, the costs attributable to cancer-directed therapy are largely 
17 underestimated. Third, although this study relies on routinely collected healthcare and administrative 
18 data with nationwide coverage in Sweden, the generalizability of our findings may be limited to 
19 countries with universal health coverage and wide access to preventive drugs. Finally, we did not assess 
20 appropriateness of prescribing: some preventive drugs reported in this study may in specific cases and 
21 for specific indications have a meaningful clinical value. For instance, the frequent use of 
22 bisphosphonates among women with breast cancer can could stem from an effort to prevent and control 
23 bone metastases.
24 Conclusion
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1 The use of preventive drugs in the last year of life is common among older adults with cancer, although 
2 there is considerable variation in use according to cancer type. In this context, the use of preventive 
3 drugs should be reconsidered in light of patient goals of care, values and preferences. Reducing the 
4 therapeutic burden in people with advanced cancer has the potential to not only reduce unnecessary 
5 adverse effects and improve patient quality of life, it also has the potential to reduce the financial burden 
6 for patients.
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Figure 1 – Study population flowchart
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Table 1 – Characteristics of older adults who died with solid cancer in Sweden, 2007–2013
Sex, No. (%)
Men 83 429 (55.2)
Women 67 772 (44.8)
Age at time of death, years
Mean (SD) 81.3 (8.1)
65 to 74 years 35 690 (23.6)
75 to 84 years 56 950 (37.7)
85 to 94 years 52 474 (34.7)
95 years and older 6087 (4.0)
Level of education, No. (%)
Primary education 71 661 (48.9)
Secondary education 57 937 (39.5)
Tertiary education 17 030 (11.6)
Living arrangement, No. (%)
Community 123 702 (81.8)
Nursing home 27 499 (18.2)
Place of death, No. (%)
Usual place of living 80,439 (53.2)
Hospital facility 70,762 (46.8)
Primary malignancy, No. (%)
Respiratory organs 18 435 (12.2)
Esophagus and stomach 5014 (3.3)
Colon-rectum 16 102 (10.6)
Liver and intrahepatic bile duct 3711 (2.5)
Pancreas 7808 (2.5)
Other digestive organs 3643 (2.4)
Breast 9920 (6.6)
Urinary tract 10 231 (6.8)
Male genital organs 25 642 (17.0)
Female genital organs 6868 (4.5)
Melanoma of skin 2651 (1.8)
Brain and meninges 2266 (1.5)
Unknown primary site 4030 (2.7)
Other primary malignancy 16 502 (10.9)
Multiple solid tumors 18 378 (12.2)
Time between diagnosis and death, No. (%)
More than 12 months 86 032 (60.0)
6 to 12 months 16 440 (11.5)
Less than 6 months 40 866 (28.5)
Number of chronic comorbidities, No. (%)
Mean (SD) 4.5 (2.8)
0 6216 (4.1%)
1 14 242 (9.4%)
2 19 570 (12.9%)
3 22 039 (14.6%)
4 21 529 (14.2%)
≥5 67 605 (44.7%)
Main chronic comorbidities, No. (%)
Hypertension 66 553 (44.0%)
Ischemic heart disease 50 896 (33.7%)
Heart failure 42 049 (27.8%)
Atrial fibrillation 36 584 (24.2%)
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Diabetes 31 279 (20.7%)
Cerebrovascular disease 28 730 (19.0%)
Cataract and other lens diseases 24 388 (16.1%)
COPD, emphysema, chronic bronchitis 22 465 (14.9%)
Dementia 17 784 (11.8%)
Missing values: education (n=4573, 3%), time from diagnosis to death (n=7863, 
5.2%).
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Table 2 – Use of preventive drugs during the last year of life of older adults (≥65 years) with solid cancer in Sweden, 2007–2013
Prevalence (n=151 201)
12th month 
before death
Last month 
before death Absolute change
Continuationb until 
the final month of life
Initiationc during 
the last year of life
Percent Percent Percent points (95%CI)a Percent (95%CI) Percent (95%CI)
Drugs used in diabetes 14.0% 14.9% +0.9 (0.6 to 1.2) 87.3 (86.8 to 87.7) 3.6 (3.5 to 3.7)
Insulin and analogues 7.6% 10.0% +2.4 (2.2 to 2.6) 89.3 (88.8 to 89.9) 4.0 (3.9 to 4.1)
Blood glucose-lowering drugs 8.7% 7.1% -1.6 (-1.8 to -1.4) 68.2 (67.4 to 69.0) 1.8 (1.7 to 1.9)
Vitamins 8.2% 9.2% +1.0 (0.8 to 1.2) 64.9 (64.1 to 65.7) 6.7 (6.6 to 6.8)
Mineral supplements 14.7% 19.2% +4.5 (4.2 to 4.8) 68.4 (67.7 to 69.9) 14.2 (14.0 to 14.4)
Calcium 10.5% 11.1% +0.6 (0.4 to 0.8) 65.7 (64.9 to 66.4) 6.5 (6.4 to 6.7)
Potassium 4.6% 7.8% +3.2 (3.0 to 3.4) 64.5 (63.3 to 65.6) 6.8 (6.6 to 6.9)
Antithrombotic agents 46.6% 48.1% +1.5 (1.1 to 1.9) 79.2 (78.9 to 79.5) 28.2 (27.9 to 28.5)
Vitamin K antagonists 7.7% 5.6% -2.1 (-2.3 to -1.9) 47.6 (46.7 to 48.5) 3.8 (3.7 to 3.9)
Heparin group 2.7% 10.0% +7.3 (7.1 to 7.5) 49.3 (47.8 to 51.9) 14.9 (14.6 to 15.9)
Platelet aggregation inhibitors 37.7% 36.2% -1.5 (-1.8 to -1.2) 77.4 (77.1 to 77.8) 13.4 (13.2 to 13.6)
Drugs used in the treatment of hypertension 60.4% 60.1% -0.3 (-0.6 to 0.0) 86.4 (86.2 to 86.7) 23.2 (22.9 to 23.6)
Low-ceiling diuretics 6.3% 5.2% -1.1 (-1.3 to -0.9) 61.2 (60.2 to 62.1) 1.9 (1.8 to 1.9)
Potassium-sparing agents 7.3% 11.2% +3.9 (3.7 to 4.1) 69.0 (68.1 to 69.9) 7.6 (7.5 to 7.8)
Beta blocking agents 37.5% 38.2% +0.7 (0.4 to 1.0) 82.9 (82.6 to 83.3) 13.3 (13.1 to 13.6)
Calcium channel blockersd 18.9% 15.9% -3.0 (-3.3 to -2.7) 68.8 (68.2 to 69.3) 4.9 (4.7 to 5.7)
ACE inhibitors 20.3% 18.5% -1.8 (-2.1 to -1.5) 71.8 (71.3 to 72.3) 6.6 (6.4 to 6.7)
Angiotensin II antagonists 11.7% 9.9% -1.8 (-2.0 to -1.6) 71.3 (70.6 to 71.9) 2.4 (2.3 to 2.4)
Lipid modifying agents 21.5% 16.8% -4.7 (-5.0 to -4.4) 65.0 (64.4 to 65.5) 5.4 (5.3 to 5.5)
HMG CoA reductase inhibitors 21.0% 16.3% -4.7 (-5.0 to -4.4) 64.9 (64.4 to 65.4) 4.9 (4.7 to 5.6)
Bisphosphonates 4.2% 3.9% -0.3 (-0.4 to -0.2) 56.6 (55.3 to 57.8) 2.8 (2.7 to 2.9)
Anti-anemic preparations 25.7% 30.4% +4.7 (4.4 to 5.0) 79.7 (79.3 to 82.1) 17.6 (17.4 to 17.8)
Iron preparations 7.4% 11.0% +3.6 (3.4 to 3.8) 55.8 (54.9 to 56.8) 11.1 (11.0 to 11.3)
Vitamin B12 and folic acid 21.0% 23.2% +2.2 (1.9 to 2.5) 82.4 (82.0 to 82.8) 8.9 (8.7 to 9.1)
Abbreviations: CI, confidence interval; ACE, angiotensin-converting-enzyme 
a Difference in proportions
b Proportion of older adults who received drugs during the last month before death, among those exposed 12 months before death
c Proportion of older adults who received drugs during the last year of life, among those not exposed 12 months before death
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d Excluding selective calcium channel blockers with direct cardiac effects (ATC code C08D)
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Table 3 – Drug costs during the final year of life, by cancer type
Total costs for prescription drugs,
per capita, US $a
Costs for preventive drugs, per 
capita, US $b
Proportion of total drug costs 
dedicated to preventive agents, %Decedents,
No.
Median (IQR) ß (95% CI)c Median (IQR) ß (95% CI)c Total last year of life 12
th month Last month
Respiratory organs 18 435 1371 (662-2619) Ref 205 (61-523) Ref 23.6% 24.6% 21.8%
Esophagus and stomach 5014 1145 (552-2267) -122 (-178 to -65) 199 (68-479) 6 (-4 to 16) 22.9% 28.1% 15.2%
Colorectal 16 102 1074 (538-2107) -161 (-199 to -122) 209 (72-479) 11 (4 to 18) 26.5% 28.3% 21.1%
Liver and intrahepatic bile duct 3711 1079 (505-2117) -224 (-288 to -161) 222 (82-514) 19 (7 to 31) 23.7% 23.9% 23.6%
Pancreas 7808 1263 (627-2353) -47 (-94 to 1) 213 (69-520) 13 (5 to 22) 23.0% 24.8% 20.6%
Other digestive organs 3643 1041 (500-2110) -162 (-227 to -98) 191 (65-426) -7 (-19 to 5) 12.8% 12.5% 13.0%
Breast 9920 1811 (851-3410) 528 (482 to 575) 218 (81-528) 19 (11 to 28) 26.3% 26.5% 24.1%
Urinary tract 10 231 1221 (626-2274) -113 (-158 to -69) 232 (93-508) 11 (3 to 19) 25.1% 26.1% 21.1%
Male genital organs 25 642 3073 (1593-4559) 1826 (1790 to 1863) 209 (80-450) 13 (6 to 19) 13.3% 13.2% 12.7%
Female genital organs 6868 1350 (675-2568) 39 (-12 to 91) 239 (86-573) 27 (18 to 36) 26.5% 26.2% 23.3%
Melanoma of skin 2651 1015 (520-1944) -165 (-239 to -91) 200 (68-458) 12 (-2 to 25) 25.6% 27.1% 22.8%
Brain and meninges 2266 1216 (640-2190) -149 (-227 to -70) 205 (63-572) 3 (-11 to 17) 27.7% 28.6% 24.1%
Unknown primary site 4030 961 (475-1816) -224 (-286 to -162) 203 (82-431) 12 (0 to 23) 22.6% 22.2% 23.5%
Other primary malignancy 16 502 1185 (627-2234) -81 (-120 to -42) 221 (93-444) 4 (-3 to 12) 19.8% 20.4% 19.1%
Multiple solid tumors 18 378 1746 (796-3409) 342 (305 to 379) 219 (74-545) 13 (7 to 20) 18.9% 18.8% 16.9%
Total cohort 151 201 1482 (700-2986) 213 (77-490) 20.2% 20.5% 18.5%
Abbreviation: IQR, Inter-quartile range.
a Expenditures for all prescription drugs dispensed in community pharmacies (ATC codes A to S)
b Expenditures for the prescription drugs mentioned in Table 2 (ATC codes available in Appendix eTable 2)
c Quantile regression model adjusted for sex, age at death, number of chronic diseases, living arrangement, and education (missing values: 4573). β coefficients can be interpreted as 
the adjusted median difference in costs compared to decedents with cancer of the respiratory organs.
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1 Abstract
2 Background: The continuation of preventive drugs for older patients with advanced cancer has come 
3 under scrutiny since these drugs are unlikely to achieve their clinical benefit during the patients’ 
4 remaining lifespan.
5 Patients and methods: nationwide cohort study of older adults (≥65 years) with solid cancer who died 
6 between 2007 and 2013 in Sweden, using routinely collected data with record linkage. We calculated 
7 the monthly utilization and cost of preventive drugs throughout the last year before death.
8 Results: Among 151 201 older patients who died with cancer (mean age 81.3 [SD, 8.1] years), the 
9 average number of drugs increased from 6.9 to 10.1. Preventive drugs were frequently continued until 
10 the final month of life, including antihypertensives, platelet aggregation inhibitors, anticoagulants, 
11 statins, and oral antidiabetics. Median drug costs amounted to $1482 (interquartile range [IQR] $700–
12 $2896]) per person, including $213 (IQR $77–$490) for preventive therapies. Compared to older adults 
13 who died with lung cancer ($205, IQR $61–$523), costs for preventive drugs were higher among older 
14 adults who died with pancreatic cancer (adjusted median difference [AMD] $13, 95% CI $5–$22), or 
15 gynecological cancers (AMD $27, 95% CI $18–$36). There was no decrease in the cost of preventive 
16 drugs throughout the last year of life.
17 Conclusion: preventive drugs are commonly prescribed during the last year of life of older adults with 
18 cancer and are often continued until the final weeks before death. Adequate deprescribing strategies are 
19 warranted to reduce the burden of drugs of limited clinical benefit near the end of life.
20 Keywords: palliative care; end-of-life; drug prescribing; deprescribing
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1 Introduction
2 In high-income countries, people aged 70 years and older now account for almost two-thirds of cancer-
3 related deaths.1 Chronic multimorbidity has thus become the norm rather than the exception in 
4 oncology2, and is associated with poorer chances of survival and with a higher burden of functional 
5 impairments and physical symptoms.3 Multimorbidity also comes with a higher burden of long-term 
6 pharmacological treatments. In the United States and in Europe, about 40% of people aged 65 years or 
7 older use 5 or more drugs concomitantly.4,5 This polypharmacy is particularly problematic among older 
8 people with advanced cancer6, since the potential to develop serious drug–drug interactions is amplified 
9 by the use of anticancer agents and complementary medicines.7,8 Moreover, the probability of 
10 experiencing adverse drug reactions increases because the main pharmacokinetic parameters are 
11 affected not only by age but also by the physiological impact of cancer (e.g. modified drug absorption 
12 due to gastrointestinal symptoms or to impairments in the gut wall function, decrease in the volume of 
13 distribution caused by weight loss, renal impairment due to the nephrotoxicity of chemotherapy).9,10 
14 Beyond pharmacology, polypharmacy in the context of advanced cancer also raises important questions 
15 from a clinical and ethical viewpoint. As cancer progresses and prognosis worsens, the net benefit of 
16 each additional medicine gradually decreases while the risk of harm increases. This “law of diminishing 
17 returns” makes the continuation or initiation of long-term treatments particularly questionable for older 
18 patients with advanced cancer. Preventive drugs are prescribed either to avert or delay the onset of a 
19 disease among individuals who are considered at high risk of developing that disease in the future 
20 (primary prevention), or to avoid the recurrence of a condition that the patient experienced in the past 
21 (secondary prevention). These drugs typically need several years before the physiological and 
22 biological changes that they produce translate into measurable and clinically meaningful health 
23 outcomes. Thus, the time-until-benefit of preventive agents is often much longer than the remaining 
24 lifespan of older adult with serious illness.11 Recent randomized controlled trials show that lipid-
25 lowering medications can safely be deprescribed among older adults with limited life expectancy, and 
26 that the discontinuation of antihypertensives among individuals without cardiovascular disease is safe 
Page 29 of 70 Cancer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
5 / 25
1 in the short term.12,13 Other long-term treatments such as bisphosphonates retain their effect 3 to 5 years 
2 after their withdrawal.14 Nevertheless, a handful of observational studies have reported that preventive 
3 medications are prescribed during the last year of life of patients with life-limiting disease, and have 
4 cast doubt upon the benefit of these treatments.15 There is limited investigation to date of the 
5 continuation and discontinuation of medications throughout the last months of life and with little 
6 information about the costs of these medications and about potential variation across cancer types. The 
7 aim of the current study was therefore to evaluate the prescribing of preventive drugs throughout the 
8 final year of life of older adults who died with cancer across Sweden, and to estimate the direct costs 
9 of preventive drugs.
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1 Methods
2 Study design and data
3 This was a retrospective cohort study based on routinely collected data in Sweden, a country with a 
4 universal healthcare system. Data from the National Cause of Death Register were linked through 
5 deterministic matching to the Total Population Register, the National Patient Register, the Swedish 
6 Prescribed Drugs Register, the Social Services Register, and the Swedish Register of Education. The 
7 Regional Ethical Review Board in Stockholm approved the study.
8 Study population
9 We included older adults aged ≥65 years who died in Sweden between 2007 and 2013, as these were 
10 the most recent available data. Decedents were considered as eligible for inclusion if a diagnosis of 
11 solid cancer (International Classification of Diseases [ICD], 10th revision codes C00–C76 and C80) was 
12 reported either in a hospital discharge report during the last 2 years of life, or as an underlying or 
13 contributing cause of death. We decided a priori to exclude decedents with missing cause of death, 
14 those with missing drug prescription history throughout the last 6 months of life, and those who 
15 remained hospitalized continuously during the last 3 months before death. Older adults with 
16 concomitant hematological malignancies (ICD-10 codes C81–C95) were also excluded, in order to 
17 select a homogenous population of individuals diagnosed only with solid cancer. Previous studies have 
18 indeed shown that persons with hematological malignancies experience a rapid functional decline at the 
19 end of life, which makes survival prediction particularly challenging. The potential for cure until late 
20 in the course of the disease trajectory differentiates these older patients from those dying with solid 
21 cancer.16,17
22 Outcomes
23 Utilization and cost of preventive drugs during the last 12 months of life were the main study outcomes. 
24 Preventive drugs with questionable benefit near the end of life have been identified in a recent 
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1 systematic review of the literature15, and include drugs for diabetes, vitamins, mineral supplements, 
2 antithrombotic agents, antihypertensives, statins, bisphosphonates, and medications for chronic anemia. 
3 The list of corresponding Anatomical Therapeutic Chemical (ATC) classification codes is available in 
4 Supplementary eTable 1. 
5 We computed monthly exposure to specific drug classes based on data from the Swedish Prescribed 
6 Drugs Register, which contains detailed information about all prescription drugs delivered in 
7 community pharmacies in Sweden since 2005 (including drugs dispensed to nursing home residents, at 
8 the exception of a few facilities with their own drug storeroom). Methods for constructing periods of 
9 drug exposure have been presented in detail elsewhere 5,18, and are illustrated in eFigure 1A. 
10 Continuation of preventive drugs was calculated as the proportion of older adults who were still using 
11 preventive drugs during the last month before death among those exposed one year before, while 
12 initiation was calculated the proportion of older adults who started using preventive drugs during the 
13 last year of life. Drug costs were estimated through a two-step approach, as described in eFigure 1B. 
14 We first divided the total cost of each purchase by the number of days covered to obtain the average 
15 daily cost. Second, we multiplied this average daily cost by the expected number of days of exposure 
16 during a given month, which allowed for distributing drug costs according to the assumed length of 
17 exposure. This approach provides a more realistic estimate of the costs, instead of artificially 
18 concentrating all expenditures at the purchase date. Drug costs were standardized using the harmonized 
19 index of consumer prices (HICP) with 2013 as reference year in order to correct for inflation over time 
20 and were then converted from the Swedish currency SEK into US dollars (USD) based on the European 
21 Central Bank average exchange rate from 1 January to 31 December 2013 to facilitate international 
22 comparisons (1 SEK = 0.1535 USD) .
23 Assessment of individual characteristics
24 Sex and date of birth were extracted from the Total Population Register and cross-validated with data 
25 reported on study participants’ death certificates. We categorized solid malignancies into 14 distinct 
26 locations. Details about the corresponding ICD-10 codes are presented in eTable 2. The overall burden 
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1 of chronic multimorbidity was measured with a recently validated tool that captures a set of 60 distinct 
2 chronic diseases based on different data sources (contributing causes of deaths, inpatients and 
3 outpatients diagnoses reported during the last 3 years of life, and specific drugs unequivocally linked 
4 to chronic conditions).19 Living arrangement at time of death was defined as “community” or “nursing 
5 home”, while the place of death was reported as either “hospital” or “usual place of living”. The 
6 decedents’ level of education was categorized into “primary”, “secondary”, and “tertiary” education in 
7 accordance with the International Standard for Classification of Education.
8 Statistical analysis
9 Multivariable quantile regressions were used to model drug costs across different cancer types, while 
10 controlling for sex, age, number of chronic diseases, living arrangement, and level of education. While 
11 linear regression allows for modeling the mean of an outcome, quantile regression is used to model 
12 quantiles of the outcome when the distribution of the outcome is highly skewed.20 Beta coefficients 
13 obtained from quantile regression models can be interpreted as the adjusted median difference (AMD) 
14 in costs compared with the reference group, and are reported together with their 95% CIs. We compared 
15 the results with estimates drawn from generalized linear models with log link function and gamma 
16 distribution, to ensure that the average median effects reported in our study are concordant (in both 
17 direction and magnitude) with average mean effects.21 Variations in the cost of preventive drugs were 
18 then represented graphically in a series of contour graphs plotting the average cost by age at death and 
19 number of comorbidities. Two sets of sensitivity analyses were performed to mitigate the risk of bias 
20 due to the potentially unpredictable time of death of older adults with cancer, which would explain why 
21 preventive drugs were continued until the very end of life: we first excluded patients whose underlying 
22 cause of death suggested an acute and sudden fatal event (eTable 4);  we then stratified the main 
23 analyses according to the time between cancer diagnosis and death, separating decedents who were 
24 diagnosed more than 12 months before death from those who were diagnosed during the last 6 months 
25 of life. Individuals with missing data for the time between diagnosis and death (n=7863, 5.2%) were 
26 excluded from this sensitivity analysis. Statistical analyses were performed using JMP version 13.0 
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1 (SAS Institute Inc) and Stata version 14.1 (StataCorp LP). This study adheres to the RECORD  
2 guidelines (Supporting file).22
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1 Results
2 Characteristics of the study population
3 Among a total of 165 821 older adults who died with cancer in Sweden between 2007 and 2013, 151 201 
4 (91.2%) met our eligibility criteria (Figure 1). Mean age at time of death was 81.3 years (SD, 8.1), 45% 
5 of decedents were women, 18% lived in nursing home facilities, and 47% died in hospitals. As shown 
6 in Table 1, the most common cancer types affected male genital organs (17%), respiratory organs 
7 (12%), and colon-rectum (11%). A large majority of patients had been diagnosed with cancer more than 
8 12 months (60%), or between 6 to 12 months (12%) before death. Hypertension, ischemic heart disease, 
9 heart failure, atrial fibrillation, and type 2 diabetes were the most commonly diagnosed comorbidities. 
10 Older adults who died without cancer reported as cause of death on their death certificate (n=29 984, 
11 19.8%) were, on average, older, lived more often in nursing homes, and had a greater number of chronic 
12 comorbidities than those who died from cancer (eTable4).
13 Use of preventive drugs
14 Throughout the last year of life, the mean number of prescribed drugs increased from 6.9 to 10.1 (mean 
15 difference 2.1, 95% CI 2.0–2.2) and the proportion of individuals using ≥10 drugs rose from 26% to 
16 52%. Preventive drugs were frequently prescribed near the end of life (Table 2). Antihypertensives were 
17 prescribed to 60.1% of the decedents during their last month of life, including beta-blockers (38.2%), 
18 angiotensin-converting-enzyme inhibitors (18.5%), and calcium channel blockers (15.9%). 
19 Antithrombotic agents, anti-anemics, lipid-lowering drugs, mineral supplements, and drugs for diabetes 
20 were also commonly prescribed. We observed little change in the use of preventive drugs over the 
21 course of the last year before death. The proportion of older adults who continued therapy until the final 
22 month of life ranged from 56.6% for bisphosphonates, to 65% for statins and vitamins, up to ≥80% for 
23 insulin, beta-blockers, and vitamin B12 or folic acid. Overall, 28.2% of decedents initiated 
24 antithrombotic agents (including 13.4% platelet aggregation inhibitors) during their last year of life, 
25 23.2% initiated high-blood pressure medications (including 13.3% beta-blockers), and 4.9% started 
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1 statins. Differences in the use of preventive drugs across cancer types are reported in eTable 5. In 
2 sensitivity analyses, results remained very similar after excluding individuals who died from acute and 
3 possibly unpredictable causes of death (eTable 6), or while comparing patients who had been diagnosed 
4 with cancer >12 months before death to individuals who were diagnosed closer to death (eTable 7). 
5 Drug costs during the last year of life
6 The median drug cost during the last year of life was $1482 (interquartile range [IQR] $700–$2896]) 
7 per person, ranging from $961 among decedents with cancers of unknown primary site, to $1811 among 
8 women with breast cancer, up to $3073 among men with cancers affecting male genital organs (Table 
9 3). After adjusting for multiple confounders, we found significantly higher costs for patients with breast 
10 cancer, gynecological cancers, cancers of male genital organs, and multiple solid tumors, compared 
11 with individuals who died with lung cancer. Median monthly drug costs increased from $80 to $153 
12 over the course of the last year of life, although there was significant variation according to the type of 
13 cancer (eTable 8).
14 The median cost for preventive drugs during the last year of life amounted to $213 (IQR $77–$490) in 
15 the total study population and varied across cancer types. Compared to older adults who died with lung 
16 cancer ($205, IQR $61–$523), those who died with pancreatic cancer (adjusted median difference 
17 [AMD] $19, 95% CI $7–$31), breast cancer (AMD $19, 95% CI $11–$28), and gynecological cancers 
18 (AMD $27, 95% CI $18–$36) had the highest costs per person. Throughout the last year of life, the 
19 proportion of total drug costs corresponding to preventive drugs was 20.2%; this proportion decreased 
20 from 20.5% during the 12th month before death to 18.5% during the last month before death. However, 
21 despite this relative reduction, we found an absolute increase in the costs owing to preventive drugs 
22 (eTable 9). Overall, costs were highest among older adults aged less than 80 years and among those 
23 who had ≥5 chronic comorbidities, although our data shows that women with breast cancer had 
24 significantly higher costs for preventive drugs even with a low burden of chronic multimorbidity 
25 (eFigure 2). In sensitivity analyses, we found only marginal differences according to the time between 
26 diagnosis and death (eTable 10).
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1 Discussion
2 This large nationwide study has three main findings. First, a substantial share of older adults who die 
3 with solid cancer continues to receive preventive drugs until the final month of life. Second, preventive 
4 drugs account for around one fifth of the total costs of prescribed drugs, and this proportion decreases 
5 only slightly as death approaches. Third, there are important differences between cancer types in the 
6 use and costs of preventive drugs, which can only partly be explained by age and chronic 
7 multimorbidity. 
8 Our study builds on previous work exploring the utilization of preventive drugs in terminally ill 
9 patients.23,24 In Australia, Currow et al. showed that, patients were prescribed on average 2.6 drugs for 
10 managing comorbid conditions at the time of palliative care referral.25 Many patients who receive 
11 preventive cardiovascular drugs continue to do so until the very end of life.26,27 For instance, the 
12 prescribing of antihypertensive agents and platelet aggregation inhibitors is commonplace among 
13 hospice patients with advanced cancer.28 Recent studies have also shown that polypharmacy increases 
14 near the end of life, which is fueled not only by symptomatic drugs but also by the continuation of 
15 preventive agents until the very last weeks of life.18,24
16 The frequent continuation of long-term preventive drugs is indicative of insufficient deprescribing 
17 strategies at the end of life. Although the preventive drugs reported in our study are most often 
18 pharmacologically and clinically appropriate in the general population, their use in the context of 
19 limited life expectancy and palliative goals of care should be examined critically.29,30 Preventive 
20 medicines are not necessarily inappropriate at the end of life, as some may have palliative indications 
21 to avert distressing symptoms or to avoid serious complications (e.g. anticoagulants for managing 
22 cancer-related venous thrombosis). However, the large proportion of older adults with cancer who 
23 continue to receive statins, antihypertensives, vitamins and mineral supplements throughout the last 
24 year of life does suggest the existence of routine-based prescribing practices that contribute to low-
25 value care. Our finding that older adults with poor-prognosis cancers (e.g. brain, lung, liver, pancreas) 
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1 were just as likely as those with less aggressive disease to use preventive drugs during their last month 
2 of life suggests that there is room for deprescribing.
3 The question of whether drug treatments should be initiated or continued near the end of life is at the 
4 center of the Choosing Wisely campaign, which has been endorsed by the American Society of Clinical 
5 Oncology, the American Geriatrics Society, and the American Medical Directors Association. It is, for 
6 instance, explicitly recommended to refrain from using lipid-lowering agents in older patients with 
7 limited life expectancy. Evidence from a recent randomized controlled trial shows that discontinuing 
8 statins in this population is safe and can result in improved quality of life.12 Three components seem 
9 essential to reduce the burden of preventive drugs of limited benefit. First, timely physician-patient 
10 communication is needed to evaluate whether the prescribed treatments are concordant with the patient 
11 goals of care. Second, physicians should carefully consider whether the prescribed drugs are likely to 
12 achieve their benefit within the patients’ remaining lifetime. Third, the decision to initiate, continue or 
13 discontinue preventive treatments should account for the risk of the patient coming to harm.
14 From a health economics perspective, it can be argued that drugs account for only small share of the 
15 total healthcare expenditure, with hospital and long-term care being the major sources of medical 
16 spending at the end of life. In the United States, drugs-related costs (including drugs administered 
17 during hospital stays) amount to around 4% of the entire medical expenditure during the last year of 
18 life.31 However, at the patient level, these costs are substantial and may contribute to the ‘financial 
19 toxicity’ of treatments, especially in countries with no universal healthcare insurance coverage.32 It is 
20 worth noting that drug prices are generally much lower in Europe than in the United States, owing for 
21 the most part to strong price regulation within the European Union. In 2017, pharmaceutical 
22 expenditures amounted to $1162 per capita in the United States compared with $479 in Sweden.33 
23 Moreover, indirect costs (e.g. cost of International Normalized Ratio-testing associated with use of 
24 warfarin) and induced costs (e.g. hospital expenditures caused by severe adverse drug reactions) of drug 
25 prescribing also contribute to the overall burden of drug costs. 
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1 This is the first nationwide study that has explored drug utilization in the last year of life according to 
2 cancer type, and that has investigated the costs associated with these drugs. However, we acknowledge 
3 a number of limitations. First, it is possible that a fraction of patients included in the cohort died from 
4 sudden and totally unexpected deaths, which could explain why preventive drugs were continued until 
5 the time of death. Retrospective cohorts of decedents are indeed prone to confounding-by-indication 
6 bias and tend to underestimate the prognostic uncertainty surrounding end-of-life decisions.34 However, 
7 sensitivity analyses were performed in an attempt to separate sudden from non-sudden deaths, and 
8 showed only marginal differences regarding patterns of drug utilization at the end of life. Second, 
9 routinely collected data about drug dispensing do not allow for assessing whether drugs are actually 
10 consumed by patients, and do not provide information about dosage modifications that may occur 
11 between two refills. It is possible that some drugs were tapered off near the end of life, which our data 
12 would not reflect. Moreover, the estimations of drug costs relied on the assumption that patients used 
13 their treatments according to the prescribed daily dose. Although this assumption is unlikely at the 
14 individual level, it is reasonable to assume that, at a population level, variations from one patient to 
15 another cancel each other out. Also, since drugs administered during hospitalizations are not collected 
16 in the Swedish Prescribed Drugs Register, the costs attributable to cancer-directed therapy are largely 
17 underestimated. Third, although this study relies on routinely collected healthcare and administrative 
18 data with nationwide coverage in Sweden, the generalizability of our findings may be limited to 
19 countries with universal health coverage and wide access to preventive drugs. Finally, we did not assess 
20 appropriateness of prescribing: some preventive drugs reported in this study may in specific cases and 
21 for specific indications have a meaningful clinical value. For instance, the frequent use of 
22 bisphosphonates among women with breast cancer could stem from an effort to prevent and control 
23 bone metastases.
24 Conclusion
Page 39 of 70 Cancer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
15 / 25
1 The use of preventive drugs in the last year of life is common among older adults with cancer, although 
2 there is considerable variation in use according to cancer type. In this context, the use of preventive 
3 drugs should be reconsidered in light of patient goals of care, values and preferences. Reducing the 
4 therapeutic burden in people with advanced cancer has the potential to not only reduce unnecessary 
5 adverse effects and improve patient quality of life, it also has the potential to reduce the financial burden 
6 for patients.
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Table 1 – Characteristics of older adults who died with solid cancer in Sweden, 2007–2013
Sex, No. (%)
Men 83 429 (55.2)
Women 67 772 (44.8)
Age at time of death, years
Mean (SD) 81.3 (8.1)
65 to 74 years 35 690 (23.6)
75 to 84 years 56 950 (37.7)
85 to 94 years 52 474 (34.7)
95 years and older 6087 (4.0)
Level of education, No. (%)
Primary education 71 661 (48.9)
Secondary education 57 937 (39.5)
Tertiary education 17 030 (11.6)
Living arrangement, No. (%)
Community 123 702 (81.8)
Nursing home 27 499 (18.2)
Place of death, No. (%)
Usual place of living 80,439 (53.2)
Hospital facility 70,762 (46.8)
Primary malignancy, No. (%)
Respiratory organs 18 435 (12.2)
Esophagus and stomach 5014 (3.3)
Colon-rectum 16 102 (10.6)
Liver and intrahepatic bile duct 3711 (2.5)
Pancreas 7808 (2.5)
Other digestive organs 3643 (2.4)
Breast 9920 (6.6)
Urinary tract 10 231 (6.8)
Male genital organs 25 642 (17.0)
Female genital organs 6868 (4.5)
Melanoma of skin 2651 (1.8)
Brain and meninges 2266 (1.5)
Unknown primary site 4030 (2.7)
Other primary malignancy 16 502 (10.9)
Multiple solid tumors 18 378 (12.2)
Time between diagnosis and death, No. (%)
More than 12 months 86 032 (60.0)
6 to 12 months 16 440 (11.5)
Less than 6 months 40 866 (28.5)
Number of chronic comorbidities, No. (%)
Mean (SD) 4.5 (2.8)
0 6216 (4.1%)
1 14 242 (9.4%)
2 19 570 (12.9%)
3 22 039 (14.6%)
4 21 529 (14.2%)
≥5 67 605 (44.7%)
Main chronic comorbidities, No. (%)
Hypertension 66 553 (44.0%)
Ischemic heart disease 50 896 (33.7%)
Heart failure 42 049 (27.8%)
Atrial fibrillation 36 584 (24.2%)
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Diabetes 31 279 (20.7%)
Cerebrovascular disease 28 730 (19.0%)
Cataract and other lens diseases 24 388 (16.1%)
COPD, emphysema, chronic bronchitis 22 465 (14.9%)
Dementia 17 784 (11.8%)
Missing values: education (n=4573, 3%), time from diagnosis to death (n=7863, 
5.2%).
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Table 2 – Use of preventive drugs during the last year of life of older adults (≥65 years) with solid cancer in Sweden, 2007–2013
Prevalence (n=151 201)
12th month 
before death
Last month 
before death Absolute change
Continuationb until 
the final month of life
Initiationc during 
the last year of life
Percent Percent Percent points (95%CI)a Percent (95%CI) Percent (95%CI)
Drugs used in diabetes 14.0% 14.9% +0.9 (0.6 to 1.2) 87.3 (86.8 to 87.7) 3.6 (3.5 to 3.7)
Insulin and analogues 7.6% 10.0% +2.4 (2.2 to 2.6) 89.3 (88.8 to 89.9) 4.0 (3.9 to 4.1)
Blood glucose-lowering drugs 8.7% 7.1% -1.6 (-1.8 to -1.4) 68.2 (67.4 to 69.0) 1.8 (1.7 to 1.9)
Vitamins 8.2% 9.2% +1.0 (0.8 to 1.2) 64.9 (64.1 to 65.7) 6.7 (6.6 to 6.8)
Mineral supplements 14.7% 19.2% +4.5 (4.2 to 4.8) 68.4 (67.7 to 69.9) 14.2 (14.0 to 14.4)
Calcium 10.5% 11.1% +0.6 (0.4 to 0.8) 65.7 (64.9 to 66.4) 6.5 (6.4 to 6.7)
Potassium 4.6% 7.8% +3.2 (3.0 to 3.4) 64.5 (63.3 to 65.6) 6.8 (6.6 to 6.9)
Antithrombotic agents 46.6% 48.1% +1.5 (1.1 to 1.9) 79.2 (78.9 to 79.5) 28.2 (27.9 to 28.5)
Vitamin K antagonists 7.7% 5.6% -2.1 (-2.3 to -1.9) 47.6 (46.7 to 48.5) 3.8 (3.7 to 3.9)
Heparin group 2.7% 10.0% +7.3 (7.1 to 7.5) 49.3 (47.8 to 51.9) 14.9 (14.6 to 15.9)
Platelet aggregation inhibitors 37.7% 36.2% -1.5 (-1.8 to -1.2) 77.4 (77.1 to 77.8) 13.4 (13.2 to 13.6)
Drugs used in the treatment of hypertension 60.4% 60.1% -0.3 (-0.6 to 0.0) 86.4 (86.2 to 86.7) 23.2 (22.9 to 23.6)
Low-ceiling diuretics 6.3% 5.2% -1.1 (-1.3 to -0.9) 61.2 (60.2 to 62.1) 1.9 (1.8 to 1.9)
Potassium-sparing agents 7.3% 11.2% +3.9 (3.7 to 4.1) 69.0 (68.1 to 69.9) 7.6 (7.5 to 7.8)
Beta blocking agents 37.5% 38.2% +0.7 (0.4 to 1.0) 82.9 (82.6 to 83.3) 13.3 (13.1 to 13.6)
Calcium channel blockersd 18.9% 15.9% -3.0 (-3.3 to -2.7) 68.8 (68.2 to 69.3) 4.9 (4.7 to 5.7)
ACE inhibitors 20.3% 18.5% -1.8 (-2.1 to -1.5) 71.8 (71.3 to 72.3) 6.6 (6.4 to 6.7)
Angiotensin II antagonists 11.7% 9.9% -1.8 (-2.0 to -1.6) 71.3 (70.6 to 71.9) 2.4 (2.3 to 2.4)
Lipid modifying agents 21.5% 16.8% -4.7 (-5.0 to -4.4) 65.0 (64.4 to 65.5) 5.4 (5.3 to 5.5)
HMG CoA reductase inhibitors 21.0% 16.3% -4.7 (-5.0 to -4.4) 64.9 (64.4 to 65.4) 4.9 (4.7 to 5.6)
Bisphosphonates 4.2% 3.9% -0.3 (-0.4 to -0.2) 56.6 (55.3 to 57.8) 2.8 (2.7 to 2.9)
Anti-anemic preparations 25.7% 30.4% +4.7 (4.4 to 5.0) 79.7 (79.3 to 82.1) 17.6 (17.4 to 17.8)
Iron preparations 7.4% 11.0% +3.6 (3.4 to 3.8) 55.8 (54.9 to 56.8) 11.1 (11.0 to 11.3)
Vitamin B12 and folic acid 21.0% 23.2% +2.2 (1.9 to 2.5) 82.4 (82.0 to 82.8) 8.9 (8.7 to 9.1)
Abbreviations: CI, confidence interval; ACE, angiotensin-converting-enzyme 
a Difference in proportions
b Proportion of older adults who received drugs during the last month before death, among those exposed 12 months before death
c Proportion of older adults who received drugs during the last year of life, among those not exposed 12 months before death
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d Excluding selective calcium channel blockers with direct cardiac effects (ATC code C08D)
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Table 3 – Drug costs during the final year of life, by cancer type
Total costs for prescription drugs,
per capita, US $a
Costs for preventive drugs, per 
capita, US $b
Proportion of total drug costs 
dedicated to preventive agents, %Decedents,
No.
Median (IQR) ß (95% CI)c Median (IQR) ß (95% CI)c Total last year of life 12
th month Last month
Respiratory organs 18 435 1371 (662-2619) Ref 205 (61-523) Ref 23.6% 24.6% 21.8%
Esophagus and stomach 5014 1145 (552-2267) -122 (-178 to -65) 199 (68-479) 6 (-4 to 16) 22.9% 28.1% 15.2%
Colorectal 16 102 1074 (538-2107) -161 (-199 to -122) 209 (72-479) 11 (4 to 18) 26.5% 28.3% 21.1%
Liver and intrahepatic bile duct 3711 1079 (505-2117) -224 (-288 to -161) 222 (82-514) 19 (7 to 31) 23.7% 23.9% 23.6%
Pancreas 7808 1263 (627-2353) -47 (-94 to 1) 213 (69-520) 13 (5 to 22) 23.0% 24.8% 20.6%
Other digestive organs 3643 1041 (500-2110) -162 (-227 to -98) 191 (65-426) -7 (-19 to 5) 12.8% 12.5% 13.0%
Breast 9920 1811 (851-3410) 528 (482 to 575) 218 (81-528) 19 (11 to 28) 26.3% 26.5% 24.1%
Urinary tract 10 231 1221 (626-2274) -113 (-158 to -69) 232 (93-508) 11 (3 to 19) 25.1% 26.1% 21.1%
Male genital organs 25 642 3073 (1593-4559) 1826 (1790 to 1863) 209 (80-450) 13 (6 to 19) 13.3% 13.2% 12.7%
Female genital organs 6868 1350 (675-2568) 39 (-12 to 91) 239 (86-573) 27 (18 to 36) 26.5% 26.2% 23.3%
Melanoma of skin 2651 1015 (520-1944) -165 (-239 to -91) 200 (68-458) 12 (-2 to 25) 25.6% 27.1% 22.8%
Brain and meninges 2266 1216 (640-2190) -149 (-227 to -70) 205 (63-572) 3 (-11 to 17) 27.7% 28.6% 24.1%
Unknown primary site 4030 961 (475-1816) -224 (-286 to -162) 203 (82-431) 12 (0 to 23) 22.6% 22.2% 23.5%
Other primary malignancy 16 502 1185 (627-2234) -81 (-120 to -42) 221 (93-444) 4 (-3 to 12) 19.8% 20.4% 19.1%
Multiple solid tumors 18 378 1746 (796-3409) 342 (305 to 379) 219 (74-545) 13 (7 to 20) 18.9% 18.8% 16.9%
Total cohort 151 201 1482 (700-2986) 213 (77-490) 20.2% 20.5% 18.5%
Abbreviation: IQR, Inter-quartile range.
a Expenditures for all prescription drugs dispensed in community pharmacies (ATC codes A to S)
b Expenditures for the prescription drugs mentioned in Table 2 (ATC codes available in Appendix eTable 2)
c Quantile regression model adjusted for sex, age at death, number of chronic diseases, living arrangement, and education (missing values: 4573). β coefficients can be interpreted as 
the adjusted median difference in costs compared to decedents with cancer of the respiratory organs.
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eTable 1 – List of Anatomical Therapeutic Chemical (ATC) codes corresponding to preventive 
drugs
Drug class ATC code
Drugs used in diabetes A10
Insulin and analogues A10A
Blood glucose lowering drugs A10B
Vitamins A11
Mineral supplements A12
Calcium A12A
Potassium A12B
Antithrombotic agents B01A
Vitamin K antagonists B01AA
Heparin group B01AB
Platelet aggregation inhibitors B01AC
Drugs used in the treatment of hypertension C02, C03A, C03B, C07, C08 (excl. C08D), C09
Low-ceiling diuretics C03A, C03B
Potassium-sparing agents C03D
Beta blocking agents C07
Calcium channel blockers C08, excl. C08D
ACE inhibitors C09A, C09B
Angiotensin II antagonists C09C, C09D
Lipid modifying agents C10
HMG CoA reductase inhibitors C10AA
Bisphosphonates M05BA, M05BB
Anti-anemic preparations B03
Iron preparations B03A
Vitamin B12 and folic acid B03BA, B03BB
Note: combinations of blood glucose-lowering drugs and lipid modifying agents are classified in A10B (e.g. combination 
of sitagliptin and simvastatin).
eTable 2 – List of International Classification of Diseases, 10th revision (ICD-10) codes 
corresponding to solid malignancies
Solid malignancy ICD-10 codes
Respiratory organs (incl. lung and bronchus) C30-C39
Esophagus and stomach C15-C16
Colorectal C18-C20
Liver and intrahepatic bile duct C22
Pancreas C25
Other digestive organs C15-C26
Breast C50
Urinary tract C64-C68
Male genital organs C60-C63
Female genital organs C51-C58
Melanoma of skin C43
Brain and meninges C70-C71
Unknown primary site C80
Other primary malignancy C00-14, C40-41, C44-49, C69, C72-C75
Multiple tumor sites Individuals with ≥2 distinct primary sites
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eTable 3 – List of International Classification of Diseases, 10th revision (ICD-10) codes used to identify acute and possibly unpredictable 
deaths in older adults
ICD Chapter Main criteria Conditional argument
ICD-10 codes listed as underlying cause of death Inpatient or specialized outpatient care admission in the past 5 years
Certain infectious and parasitic diseases A00; A01; A02; A03; A04; A05; A06; A07; A08; A09; A39; A40; A41; 
A499; A80; A81; A87; B371; B375; B377; B440; B441; B448; B449; B99
Diseases of the blood and blood-forming organs D611; D619; D649
Endocrine, nutritional and metabolic diseases E86
Diseases of the nervous system G000; G001; G002; G003; G009; G039; G040; G048; G049; G060; G062; 
G931; G936
Ischaemic and pulmonary heart diseases I20; I21; I23; I25; I249; I249; I255; I26; I28 No history of ischemic heart disease 
(I20-I25) or pulmonary embolism (I26)
Other forms of heart disease I30; I33; I40; I461; I469
Cerebrovascular diseases I60; I61; I62; I63; I64; I65; I66; I67 No history of cerebrovascular disease 
(I60-I69)
Diseases of arteries, arterioles and capillaries I71; I72; I74; I97
Diseases of the respiratory system J069; J09; J10; J11; J12; J13; J14; J15; J18; J22; J690; J81; J851; J852; J93; 
J958; J960
Diseases of the digestive system K250; K251; K252; K253; K254; K255; K256; K257; K259; K260; K261; 
K263; K264; K265; K266; K269; K550; K65; K720; K810; K859
Diseases of the musculoskeletal system and 
connective tissue
M726
Diseases of the genitourinary system N00; N04; N10; N17; N390; N990; N998 No history of diabetes (E10-14) or renal 
failure (N18-19)
Symptoms, signs and abnormal clinical and 
laboratory findings, not elsewhere classified
R02; R572; R570; R571
Injury, poisoning and certain other consequences 
of external causes
S065; S066; S068; S069; S071; S10-99; T00-T99
 External causes of morbidity and mortality V00-V99; X60-79; X80-84
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eTable 4 – Characteristics of older adults who died with and without cancer reported as 
cause of death
Total cohort
(n=151 201)
Cancer as cause 
of death
(n=121 217)
No cancer as 
cause of death
(n=29 984)
P-value
Sex, No. (%) <.001
Men 83 429 (55.2) 65583 (54.1%) 17846 (59.5%)
Women 67 772 (44.8) 55634 (45.9%) 12138 (40.5%)
Age at time of death, years
Mean (SD) 81.3 (8.1) 80.4 (8.0) 85.0 (7.5) <.001
65 to 74 years 35 690 (23.6) 32449 (26.8%) 3241 (10.8%) <.001
75 to 84 years 56 950 (37.7) 47443 (39.1%) 9507 (31.7%)
85 to 94 years 52 474 (34.7) 37673 (31.1%) 14801 (49.4%)
95 years and older 6087 (4.0) 3652 (3.0%) 2435 (8.1%)
Level of educationb, No. (%) <.001
Primary education 71 661 (48.9) 56733 (48.1%) 14928 (51.9%)
Secondary education 57 937 (39.5) 47266 (40.1%) 10671 (37.1%)
Tertiary education 17 030 (11.6) 13871 (11.8%) 3159 (11.0%)
Living arrangement, No. (%) <.001
Community 123 702 (81.8) 102376 (84.5%) 21326 (71.1%)
Nursing home 27 499 (18.2) 18841 (15.5%) 8658 (28.9%)
Place of death, No. (%) <.001
Usual place of living 80,439 (53.2) 67609 (55.8%) 16170 (53.9%)
Hospital facility 70,762 (46.8) 53608 (44.2%) 13814 (46.1%)
Primary malignancy, No. (%) <.001
Respiratory organs 18 435 (12.2) 17334 (14.3%) 1101 (3.7%)
Esophagus and stomach 5014 (3.3) 4751 (3.9%) 263 (0.9%)
Colon-rectum 16 102 (10.6) 14460 (11.9%) 1642 (5.5%)
Liver and intrahepatic bile duct 3711 (2.5) 3486 (2.9%) 225 (0.8%)
Pancreas 7808 (2.5) 7548 (6.2%) 260 (0.9%)
Other digestive organs 3643 (2.4) 3387 (2.8%) 256 (0.9%)
Breast 9920 (6.6) 8216 (6.8%) 1704 (5.7%)
Urinary tract 10 231 (6.8) 7406 (6.1%) 2825 (9.4%)
Male genital organs 25 642 (17.0) 19556 (16.1%) 6086 (20.3%)
Female genital organs 6868 (4.5) 5972 (4.9%) 896 (3.0%)
Melanoma of skin 2651 (1.8) 1915 (1.6%) 736 (2.5%)
Brain and meninges 2266 (1.5) 1720 (1.4%) 546 (1.8%)
Unknown primary site 4030 (2.7) 3907 (3.2%) 123 (0.4%)
Other primary malignancy 16 502 (10.9) 4251 (3.5%) 12251 (40.9%)
Multiple solid tumors 18 378 (12.2) 17308 (14.3%) 1070 (3.6%)
Number of chronic comorbidities, No. 
(%)
Mean (SD) 4.5 (2.8) 4.2 (2.7) 5.9 (3.0) <.001
0 6 216 (4.1%) 5 914 (4.9%) 302 (1.0%) <.001
1 14 242 (9.4%) 13 093 (10.8%) 1 149 (3.8%)
2 19 570 (12.9%) 17 321 (14.3%) 2 249 (7.5%)
3 22 039 (14.6%) 18 810 (15.5%) 3 229 (10.8%)
4 21 529 (14.2%) 17 611 (14.5%) 3 918 (13.1%)
≥5 67 605 (44.7%) 48 468 (40.0%) 19 137 (63.8%)
Chronic comorbidities, No. (%)
Hypertension 66 553 (44.0%) 51 519 (42.5%) 15 034 (50.1%) <.001
Ischemic heart disease 50 896 (33.7%) 35 468 (29.3%) 15 428 (51.5%) <.001
Heart failure 42 049 (27.8%) 27 563 (22.7%) 14 486 (48.3%)
Atrial fibrillation 36 584 (24.2%) 25 531 (21.1%) 11 053 (36.9%) <.001
Diabetes 31 279 (20.7%) 24 520 (20.2%) 6 759 (22.5%) <.001
Cerebrovascular disease 28 730 (19.0%) 19 320 (15.9%) 9 410 (31.4%) <.001
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Total cohort
(n=151 201)
Cancer as cause 
of death
(n=121 217)
No cancer as 
cause of death
(n=29 984)
P-value
Sex, No. (%) <.001
Cataract and other lens diseases 24 388 (16.1%) 18 789 (15.5%) 5 599 (18.7%) <.001
COPD, emphysema, chronic bronchitis 22 465 (14.9%) 17 349 (14.3%) 5 116 (17.1%) <.001
Dementia 18 629 (12.3%) 12 451 (10.3%) 6 178 (20.6%) <.001
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eTable 5 – Use of preventive drugs during the final month of life, by cancer type
Drugs used in 
diabetes Vitamins
Mineral 
supplements
Antithrombotic 
agents
Drugs used in the 
treatment of 
hypertension
Lipid modifying
agents Bisphosphonates
Anti-anemic 
preparations
% % % % % % % %
Respiratory organs 13.3% 8.5% 18.1% 47.1% 58.3% 20.7% 4.6% 23.7%
Esophagus and stomach 12.6% 7.8% 14.1% 40.9% 53.6% 15.4% 1.6% 37.1%
Colorectal 13.9% 8.6% 18.1% 43.1% 57.9% 15.2% 2.5% 34.0%
Liver and intrahepatic bile duct 25.2% 8.8% 16.7% 43.5% 70.1% 18.2% 3.2% 23.3%
Pancreas 28.1% 6.6% 18.8% 46.7% 60.6% 18.3% 2.4% 20.4%
Other digestive organs 14.1% 8.3% 19.2% 42.4% 59.4% 14.5% 2.8% 29.9%
Breast 13.3% 8.9% 25.2% 45.7% 59.8% 10.2% 9.0% 27.6%
Urinary tract 15.2% 11.0% 17.4% 50.1% 63.8% 19.2% 2.9% 34.7%
Male genital organs 13.5% 9.9% 17.4% 53.6% 60.4% 17.8% 3.3% 33.3%
Female genital organs 12.7% 9.0% 21.8% 46.2% 57.1% 12.7% 4.0% 27.9%
Melanoma of skin 14.4% 8.2% 16.4% 49.2% 63.3% 18.6% 3.5% 25.8%
Brain and meninges 20.0% 4.6% 25.1% 41.4% 54.9% 17.8% 6.9% 15.7%
Unknown primary site 15.3% 9.3% 20.3% 51.6% 65.0% 18.4% 4.0% 33.2%
Other primary malignancy 13.3% 12.4% 23.5% 55.5% 65.4% 16.5% 4.3% 35.9%
Multiple solid tumors 14.4% 8.0% 17.9% 44.6% 56.9% 16.6% 3.4% 26.9%
Total cohort 14.9% 9.2% 19.2% 48.1% 60.1% 16.8% 3.9% 30.4%
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eTable 6 – Sensitivity analysis: use of preventive drugs during the last year of life of older adults (≥65 years)
with cancer, after excluding individuals who died from acute and possibly unpredictable causes (n= 102 515)
12th month 
before death
Last month 
before death Absolute change
Percent Percent Percent points (95%CI)
Drugs used in diabetes 13.8% 14.9% 1.04 (0.7 to 1.3)
Insulin and analogues 7.4% 10.2% 2.78 (2.5 to 3)
Blood glucose-lowering drugs 8.8% 7.1% -1.71 (-1.9 to -1.5)
Vitamins 7.5% 8.5% 0.99 (0.8 to 1.2)
Mineral supplements 13.9% 18.5% 4.55 (4.2 to 4.9)
Calcium 10.0% 10.4% 0.41 (0.1 to 0.7)
Potassium 4.2% 7.6% 3.32 (3.1 to 3.5)
Antithrombotic agents 44.3% 45.6% 1.25 (0.8 to 1.7)
Vitamin K antagonists 7.2% 4.8% -2.4 (-2.6 to -2.2)
Heparin group 3.0% 11.2% 8.2 (8 to 8.4)
Platelet aggregation inhibitors 35.6% 33.3% -2.33 (-2.7 to -1.9)
Drugs used in the treatment of hypertension 58.9% 58.3% -0.59 (-1 to -0.2)
Low-ceiling diuretics 6.5% 5.2% -1.31 (-1.5 to -1.1)
Potassium-sparing agents 6.8% 11.3% 4.55 (4.3 to 4.8)
Beta blocking agents 36.4% 36.6% 0.23 (-0.2 to 0.6)
Calcium channel blockersd 18.5% 15.2% -3.3 (-3.6 to -3)
ACE inhibitors 19.7% 17.3% -2.39 (-2.7 to -2.1)
Angiotensin II antagonists 11.6% 9.5% -2.14 (-2.4 to -1.9)
Lipid modifying agents 21.6% 16.2% -5.46 (-5.8 to -5.1)
HMG CoA reductase inhibitors 21.1% 15.6% -5.51 (-5.8 to -5.2)
Bisphosphonates 4.1% 3.9% -0.23 (-0.4 to -0.1)
Anti-anemic preparations 23.5% 27.4% 3.89 (3.5 to 4.3)
Iron preparations 6.8% 10.1% 3.25 (3 to 3.5)
Vitamin B12 and folic acid 19.3% 21.1% 1.74 (1.4 to 2.1)
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eTable 7 – Sensitivity analysis: use of preventive drugs throughout the last year of life of older adults (≥65 years) with cancer, according to the 
time between cancer diagnosis and death
Time from cancer diagnosis to death
More than 12 months 6 to 12 months Less than 6 months 
12th month Last month 12th month Last month 12th month Last month
Percent Percent Percent Percent Percent Percent 
Drugs used in diabetes 13.9% 14.4% 13.4% 14.3% 14.6% 16.5%
Insulin and analogues 8.1% 9.9% 6.7% 10.1% 7.1% 10.6%
Blood glucose-lowering drugs 8.0% 6.4% 9.3% 6.4% 10.3% 9.2%
Vitamins 8.9% 9.4% 7.2% 8.5% 6.7% 8.3%
Mineral supplements 16.1% 19.9% 12.3% 18.2% 12.3% 17.8%
Calcium 11.2% 11.9% 9.0% 9.4% 9.2% 10.0%
Potassium 5.2% 8.0% 3.6% 8.0% 3.5% 7.2%
Antithrombotic agents 48.8% 49.0% 43.2% 44.7% 43.3% 47.8%
Vitamin K antagonists 8.1% 5.8% 8.0% 4.4% 7.2% 5.7%
Heparin group 4.1% 9.8% 1.6% 12.2% 0.5% 10.6%
Platelet aggregation inhibitors 38.4% 36.9% 35.2% 31.4% 36.5% 36.1%
Drugs used in the treatment of hypertension 61.3% 59.9% 58.7% 57.2% 60.1% 62.7%
Low-ceiling diuretics 5.9% 4.7% 6.7% 4.9% 7.4% 6.4%
Potassium-sparing agents 7.8% 11.2% 5.8% 11.0% 6.5% 11.2%
Beta blocking agents 38.5% 38.7% 35.9% 35.6% 36.7% 39.1%
Calcium channel blockersd 18.6% 15.1% 19.3% 14.8% 20.1% 18.7%
ACE inhibitors 20.3% 18.2% 20.5% 16.7% 20.8% 20.2%
Angiotensin II antagonists 11.6% 9.6% 12.2% 9.1% 12.4% 11.4%
Lipid modifying agents 21.1% 16.1% 23.6% 15.5% 23.2% 20.3%
HMG CoA reductase inhibitors 20.5% 15.5% 23.1% 15.1% 22.7% 19.7%
Bisphosphonates 4.5% 4.3% 3.7% 3.4% 3.7% 3.6%
Anti-anemic preparations 27.3% 30.4% 22.3% 27.6% 20.9% 27.9%
Iron preparations 8.4% 10.9% 7.0% 10.8% 5.0% 10.6%
Vitamin B12 and folic acid 22.3% 24.0% 17.9% 20.7% 18.1% 21.1%
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eTable 8 – Change in the costs of all prescription drugs throughout the final year of life, by cancer type
12th 
month
Last 
monthPrimary malignancy Decedents, No.
Median (IQR), US $ Median (IQR), US $ 
Median difference
(US $), 95% CI P value
Respiratory organs 18 435 66 (20 to 162) 160 (72 to 305) +94.3 (90.8 to 97.8) <0.001
Esophagus and stomach 5014 52 (16 to 124) 132 (56 to 293) +80.0 (74.0 to 86.0) <0.001
Colorectal 16 102 58 (21 to 132) 119 (54 to 243) +61.1 (58.1 to 64.0) <0.001
Liver and intrahepatic bile duct 3711 62 (22 to 136) 123 (55 to 247) +60.9 (54.1 to 67.7) <0.001
Pancreas 7808 57 (19 to 134) 161 (74 to 329) +104.5 (98.9 to 110.1) <0.001
Other digestive organs 3643 55 (19 to 133) 123 (55 to 267) +68.1 (61.3 to 74.8) <0.001
Breast 9920 112 (43 to 258) 173 (73 to 330) +61.0 (54.2 to 67.8) <0.001
Urinary tract 10 231 70 (27 to 152) 127 (59 to 255) +56.5 (52.4 to 60.5) <0.001
Male genital organs 25 642 183 (63 to 363) 251 (110 to 452) +67.4 (62.2 to 72.6) <0.001
Female genital organs 6868 71 (27 to 159) 138 (61 to 292) +66.5 (61.1 to 71.9) <0.001
Melanoma of skin 2651 59 (20 to 131) 117 (56 to 229) +58.6 (51.4 to 65.9) <0.001
Brain and meninges 2266 49 (12 to 125) 159 (75 to 297) +109.6 (100.6 to 118.5) <0.001
Unknown primary site 4030 58 (22 to 130) 108 (52 to 209) +50.5 (45.2 to 55.7) <0.001
Other primary malignancy 16 502 80 (36 to 165) 110 (55 to 216) +30 (27.1 to 32.8) <0.001
Multiple solid tumors 18 378 83 (28 to 216) 180 (79 to 366) +97.7 (93.4 to 101.9) <0.001
Total cohort 151 201 80 (29 to 195) 153 (68 to 314) +73.1 (71.7 to 74.4) <0.001
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eTable 9 – Change in the costs of preventive drugs throughout the final year of life, by cancer type
12th 
month
Last 
monthPrimary malignancy Decedents, No.
Median (IQR), US $ Median (IQR), US $ 
Median difference
(US $), 95% CI P value
Respiratory organs 18 435 11 (0-31) 13 (3-38) +1.89 (1.35 to 2.43) <0.001
Esophagus and stomach 5014 12 (1-31) 12 (3-33) -0.16 (-1.09 to 0.77) 0.732
Colorectal 16 102 12 (2-31) 14 (3-34) +1.33 (0.80 to 1.86) <0.001
Liver and intrahepatic bile duct 3711 14 (3-34) 15 (5-38) +1.74 (0.53 to 2.94) <0.001
Pancreas 7808 11 (0-29) 14 (3-42) +2.42 (1.61 to 3.24) <0.001
Other digestive organs 3643 12 (2-28) 12 (3-34) +0.71 (-0.30 to 1.73) 0.168
Breast 9920 13 (3-34) 14 (4-35) +0.17 (-0.51 to 0.85) 0.620
Urinary tract 10 231 15 (4-35) 15 (5-36) +0.23 (-0.47 to 0.94) 0.515
Male genital organs 25 642 14 (4-32) 14 (4-32) -0.24 (-0.65 to 0.16) 0.236
Female genital organs 6868 13 (2-34) 15 (3-45) +1.69 (0.76 to 2.63) <0.001
Melanoma of skin 2651 13 (3-31) 13 (4-34) +0.71 (-0.58 to 2.00) 0.280
Brain and meninges 2266 9 (0-30) 13 (2-40) +3.59 (2.14 to 5.03) <0.001
Unknown primary site 4030 13 (3-30) 15 (5-35) +1.48 (0.48 to 2.48) <0.001
Other primary malignancy 16 502 16 (5-34) 16 (5-35) -0.20 (-0.71 to 0.32) 0.451
Multiple solid tumors 18 378 12 (1-33) 13 (3-37) +1.01 (0.48 to 1.53) <0.001
Total cohort 151 201 13 (3–32) 14 (4–36) +0.78 (0.60 to 0.95) <0.001
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eFigure 2 – Mean costs for preventive drugs during the final year of life, by cancer type, age at 
death and number of chronic comorbidities, in US $
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eTable 10 – Sensitivity analysis: preventive drugs costs during the final year of life, by cancer type and according to the time between cancer 
diagnosis and death
Time from cancer diagnosis to death
Total
More than 12 months 6 to 12 months Less than 6 monthsPrimary malignancy
Median, US $ (P25-P75) Median (IQR), US $ Median (IQR), US $ Median (IQR), US $ 
P value
Respiratory organs 205 (61-523) 219 (71-562) 228 (71-665) 192 (51-480) <0.001
Esophagus and stomach 199 (68-479) 217 (80-543) 209 (85-535) 187 (51-439) <0.001
Colorectal 209 (72-479) 217 (76-529) 213 (77-539) 204 (65-430) <0.001
Liver and intrahepatic bile duct 222 (82-514) 229 (89-531) 240 (99-596) 222 (76-510) 0.0305
Pancreas 213 (69-520) 208 (69-511) 222 (64-620) 216 (70-510) 0.1337
Other digestive organs 191 (65-426) 198 (72-472) 198 (58-513) 196 (61-422) 0.2278
Breast 218 (81-528) 238 (88-610) 235 (92-535) 202 (72-404) <0.001
Urinary tract 232 (93-508) 236 (99-515) 252 (95-570) 222 (82-480) <0.001
Male genital organs 209 (80-450) 213 (84-461) 210 (74-449) 206 (75-428) 0.0102
Female genital organs 239 (86-573) 252 (89-635) 279 (113-723) 230 (79-491) <0.001
Melanoma of skin 200 (68-458) 204 (73-468) 213 (64-545) 187 (70-414) <0.001
Brain and meninges 205 (63-572) 191 (47-721) 251 (76-855) 205 (67-494) <0.001
Unknown primary site 203 (82-431) 215 (87-448) 217 (70-617) 211 (88-437) 0.5715
Other primary malignancy 221 (93-444) 226 (98-449) 224 (90-456) 212 (83-437) 0.009
Multiple solid tumors 219 (74-545) 224 (78-557) 236 (81-632) 190 (52-439) <0.001
Total cohort 213 (77-490) 221 (84-509) 225 (80-560) 204 (66-459) <0.001
P-values were calculated with non-parametric Wilcoxon rank sum tests stratified by primary malignancy.
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The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using 
routinely collected health data.
Item 
No.
STROBE items Location in 
manuscript where 
items are reported
RECORD items Location in 
manuscript 
where items are 
reported
Title and abstract
1 (a) Indicate the study’s design 
with a commonly used term in 
the title or the abstract (b) 
Provide in the abstract an 
informative and balanced 
summary of what was done and 
what was found
RECORD 1.1: The type of data used 
should be specified in the title or 
abstract. When possible, the name of 
the databases used should be included.
RECORD 1.2: If applicable, the 
geographic region and timeframe 
within which the study took place 
should be reported in the title or 
abstract.
RECORD 1.3: If linkage between 
databases was conducted for the study, 
this should be clearly stated in the title 
or abstract.
Abstract, line 6
Abstract, lines 5-6
Abstract, line 6
Introduction
Background 
rationale
2 Explain the scientific 
background and rationale for the 
investigation being reported
Page 4
Objectives 3 State specific objectives, 
including any prespecified 
hypotheses
Page 5, line 6
Methods
Study Design 4 Present key elements of study 
design early in the paper
Page 6, lines 2-7
Setting 5 Describe the setting, locations, 
and relevant dates, including 
periods of recruitment, exposure, 
follow-up, and data collection
Page 6, lines 2-17
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Participants 6 (a) Cohort study - Give the 
eligibility criteria, and the 
sources and methods of selection 
of participants. Describe 
methods of follow-up
Case-control study - Give the 
eligibility criteria, and the 
sources and methods of case 
ascertainment and control 
selection. Give the rationale for 
the choice of cases and controls
Cross-sectional study - Give the 
eligibility criteria, and the 
sources and methods of selection 
of participants
(b) Cohort study - For matched 
studies, give matching criteria 
and number of exposed and 
unexposed
Case-control study - For 
matched studies, give matching 
criteria and the number of 
controls per case
RECORD 6.1: The methods of study 
population selection (such as codes or 
algorithms used to identify subjects) 
should be listed in detail. If this is not 
possible, an explanation should be 
provided. 
RECORD 6.2: Any validation studies 
of the codes or algorithms used to 
select the population should be 
referenced. If validation was conducted 
for this study and not published 
elsewhere, detailed methods and results 
should be provided.
RECORD 6.3: If the study involved 
linkage of databases, consider use of a 
flow diagram or other graphical display 
to demonstrate the data linkage 
process, including the number of 
individuals with linked data at each 
stage.
Page 6, lines 8-17
Page 6, lines 10-
15
Page 6, line 5
+ Figure 1
Variables 7 Clearly define all outcomes, 
exposures, predictors, potential 
confounders, and effect 
modifiers. Give diagnostic 
criteria, if applicable.
RECORD 7.1: A complete list of codes 
and algorithms used to classify 
exposures, outcomes, confounders, and 
effect modifiers should be provided. If 
these cannot be reported, an 
explanation should be provided.
Page 6
+Appendix 
eTable 1 
Data sources/ 
measurement
8 For each variable of interest, 
give sources of data and details 
of methods of assessment 
(measurement).
Describe comparability of 
assessment methods if there is 
more than one group
Pages 6-7
Page 65 of 70 Cancer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Bias 9 Describe any efforts to address 
potential sources of bias
Page 8, lines 1-17
Study size 10 Explain how the study size was 
arrived at
N.A
Quantitative 
variables
11 Explain how quantitative 
variables were handled in the 
analyses. If applicable, describe 
which groupings were chosen, 
and why
Page 8, lines 1-17
Statistical 
methods
12 (a) Describe all statistical 
methods, including those used to 
control for confounding
(b) Describe any methods used 
to examine subgroups and 
interactions
(c) Explain how missing data 
were addressed
(d) Cohort study - If applicable, 
explain how loss to follow-up 
was addressed
Case-control study - If 
applicable, explain how 
matching of cases and controls 
was addressed
Cross-sectional study - If 
applicable, describe analytical 
methods taking account of 
sampling strategy
(e) Describe any sensitivity 
analyses
 Page 8, lines 1-17
Appendix eTables 
5, 6, 7, 8, 9 and 
10 + eFigure 2
No loss to follow-
up by design 
(retrospective 
cohort of 
decedents)
Data access and 
cleaning methods
.. RECORD 12.1: Authors should 
describe the extent to which the 
investigators had access to the database 
population used to create the study 
population.
Page 6, lines 2-7
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RECORD 12.2: Authors should 
provide information on the data 
cleaning methods used in the study.
Linkage .. RECORD 12.3: State whether the 
study included person-level, 
institutional-level, or other data linkage 
across two or more databases. The 
methods of linkage and methods of 
linkage quality evaluation should be 
provided.
Page 6, line 5
Results
Participants 13 (a) Report the numbers of 
individuals at each stage of the 
study (e.g., numbers potentially 
eligible, examined for eligibility, 
confirmed eligible, included in 
the study, completing follow-up, 
and analysed)
(b) Give reasons for non-
participation at each stage.
(c) Consider use of a flow 
diagram
RECORD 13.1: Describe in detail the 
selection of the persons included in the 
study (i.e., study population selection) 
including filtering based on data 
quality, data availability and linkage. 
The selection of included persons can 
be described in the text and/or by 
means of the study flow diagram.
Figure 1
Descriptive data 14 (a) Give characteristics of study 
participants (e.g., demographic, 
clinical, social) and information 
on exposures and potential 
confounders
(b) Indicate the number of 
participants with missing data 
for each variable of interest
(c) Cohort study - summarise 
follow-up time (e.g., average and 
total amount)
Page 9, lines 2-12
+ Table 1
Outcome data 15 Cohort study - Report numbers 
of outcome events or summary 
measures over time
Case-control study - Report 
numbers in each exposure 
Page 9-10
Table 2
Page 67 of 70 Cancer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
category, or summary measures 
of exposure
Cross-sectional study - Report 
numbers of outcome events or 
summary measures
Main results 16 (a) Give unadjusted estimates 
and, if applicable, confounder-
adjusted estimates and their 
precision (e.g., 95% confidence 
interval). Make clear which 
confounders were adjusted for 
and why they were included
(b) Report category boundaries 
when continuous variables were 
categorized
(c) If relevant, consider 
translating estimates of relative 
risk into absolute risk for a 
meaningful time period
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Discussion
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